Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Infectious Disease
•
Tuberculosis
•
Inflammatory eye disorders
•
Scleritis
•
Ophthalmology
•
General Infectious Disease
How do you approach treatment of tuberculous scleritis in pregnancy?
Related Questions
How would you approach management of incidentally identified unilateral retinal vasculitis with subsequent labs revealing +P-ANCA?
For how long do you recommend treatment for latent tuberculosis prior to initiation of anti-TNF therapy?
Do you have a preference between Quantiferon Gold and T-spot TB for screening in patients starting immunosuppressive agents?
How do you approach ongoing screening for TB in patients with a history of treated latent TB, but who have ongoing use of DMARDs and/or biologics given Quantiferon testing and PPD can remain positive?
When is it safe to resume DMARDs in a patient who was diagnosed with active TB and started on treatment?
What would be your approach to a patient with Scleroderma/Myositis overlap syndrome (+anti-Ku) and active inflammatory eye disease despite high dose mycophenolate?
What is your approach to duration of systemic antibiotics for treatment of isolated bacterial endophthalmitis in the absence of bacteremia or other deep-seated metastatic foci of infection?
What is your approach to evaluation and management of symptomatic nodular episcleritis?
What else do you consider in the differential diagnosis for pulmonary-renal syndromes if there is low clinical and serologic evidence of AAV, Goodpasture's or other rheumatologic disease (SLE, RA, APS, Scleroderma)?
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?